SINO BIOPHARM(01177) 证券时报网·2024-10-31 06:48Core Insights - China Biopharmaceutical (01177.HK) reported a strong performance in Q3, driven by the recovery of the pharmaceutical industry and accelerated R&D, production, and sales [1] - The company achieved approximately RMB 21.35 billion in revenue for the first three quarters, reflecting a year-on-year growth of about 11.9% [1] - The net profit attributable to shareholders for the first three quarters was approximately RMB 4.17 billion, showing a significant year-on-year increase of about 134.9% [1] Revenue Performance - Q3 revenue reached approximately RMB 5.47 billion, marking a year-on-year growth of about 14.3% [1] - The management highlighted that several innovative products, including Bevacizumab, Rituximab, and Trastuzumab, have been rapidly gaining market traction, contributing significantly to revenue growth [2] Profitability - The adjusted net profit attributable to shareholders for the first three quarters was approximately RMB 2.14 billion, with a year-on-year increase of about 23.7% [1] - In Q3, the net profit attributable to shareholders was approximately RMB 1.15 billion, reflecting a year-on-year growth of about 123.4% [1] Innovation and Future Outlook - The company has entered a phase of intensive innovation product harvest, having received approvals for four innovative products this year, including three Class 1 innovative drugs [1] - Future focus areas for China Biopharmaceutical include oncology, liver disease, respiratory, and surgical/pain management, with an emphasis on accelerating product launch processes [2]